Published on: 26 September 2022
In a new paper, IFPMA describes how the R&D-based pharmaceutical industry delivers products with the same quality to all countries around the world, which should facilitate reliance procedures. IFPMA notes that mutual trust between all parties is the foundation of reliance, adding that transparency is a key principle for good regulatory practice and fundamental to reliance.
